| scholarly article | Q13442814 |
| P2093 | author name string | Himisha Beltran | |
| Olivier Elemento | |||
| Jyotishman Pathak | |||
| Anthony Yu | |||
| Hannah Mitchell | |||
| Maggie Morash | |||
| Thomas Campion | |||
| P2860 | cites work | KEGG: kyoto encyclopedia of genes and genomes | Q24515297 |
| The NHGRI GWAS Catalog, a curated resource of SNP-trait associations | Q24568334 | ||
| dbSNP: the NCBI database of genetic variation | Q24608672 | ||
| Pharmacogenomics knowledge for personalized medicine | Q24623166 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| SNPedia: a wiki supporting personal genome annotation, interpretation and analysis | Q28740978 | ||
| The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies | Q28742793 | ||
| BioPortal: ontologies and integrated data resources at the click of a mouse | Q29617519 | ||
| The SIDER database of drugs and side effects | Q30002337 | ||
| Cardiovascular risk of BRCA1/2 mutation carriers: A review | Q30248813 | ||
| The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations | Q30490259 | ||
| RxNav: a web service for standard drug information. | Q33269845 | ||
| Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. | Q33671281 | ||
| Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine | Q33725390 | ||
| Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity | Q34189102 | ||
| Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems | Q34216807 | ||
| Genenames.org: the HGNC resources in 2015 | Q34445762 | ||
| Normalized names for clinical drugs: RxNorm at 6 years | Q35082977 | ||
| Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. | Q35086334 | ||
| Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity | Q35491177 | ||
| Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9 | Q35535683 | ||
| Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study | Q35990409 | ||
| A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer | Q36004460 | ||
| Pharmacogenomics as a Risk Mitigation Strategy for Chemotherapeutic Cardiotoxicity | Q36637796 | ||
| Genomic Profiling Reveals the Potential Role of TCL1A and MDR1 Deficiency in Chemotherapy-Induced Cardiotoxicity | Q36800903 | ||
| Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms | Q36804526 | ||
| Genetic susceptibility to anthracycline‐related congestive heart failure in survivors of haematopoietic cell transplantation | Q37227651 | ||
| A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. | Q37293202 | ||
| CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study | Q37350809 | ||
| Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity | Q37378179 | ||
| Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab | Q38113203 | ||
| Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity | Q38146049 | ||
| Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. | Q38390826 | ||
| Systems biology approaches to adverse drug effects: the example of cardio-oncology | Q38606067 | ||
| Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. | Q38765132 | ||
| Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity | Q38838517 | ||
| PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability | Q39879045 | ||
| Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis. | Q40863059 | ||
| Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study | Q42727098 | ||
| Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial | Q43466172 | ||
| Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer | Q45060828 | ||
| Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. | Q46008254 | ||
| Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. | Q46409053 | ||
| NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity | Q46837798 | ||
| Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients | Q49136273 | ||
| Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma | Q53564509 | ||
| Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia | Q53672562 | ||
| Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children | Q57239656 | ||
| Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer | Q58849554 | ||
| Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children | Q58862883 | ||
| Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre | Q61624905 | ||
| Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity | Q80785284 | ||
| The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms | Q85533571 | ||
| Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy | Q87354115 | ||
| P921 | main subject | pharmacogenomics | Q1152227 |
| P304 | page(s) | 168-177 | |
| P577 | publication date | 2018-05-18 | |
| P1433 | published in | AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science | Q27723308 |
| P1476 | title | CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. | |
| P478 | volume | 2017 |
| Q57823713 | Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal | cites work | P2860 |
Search more.